XTL Biopharmaceuticals Ltd. was served with a shareholder motion on August 3, 2026, seeking court authorization to file a derivative claim against the controlling shareholder and certain current and former directors and officers. The Motion alleges breaches of fiduciary duties regarding the 2024 acquisition of The Social Proxy Ltd., including failure to fund the subsidiary as committed, conflicts of interest, delayed disclosure of lost control, and financial irregularities. The subsidiary is in liquidation following a February 22, 2026 court order. The petitioner seeks approximately NIS 100 million in compensation for destroyed value, disgorgement of benefits, appointment of a forensic accountant, and legal fees. XTL Biopharmaceuticals Ltd. believes the claims are meritless and intends to respond fully. This company operates in the biotechnology industry, focusing on drug discovery and development.

XTL Biopharmaceuticals Ltd. received a letter from Nasdaq confirming it has regained compliance with several listing rules, including the Bid Price Rule and the Equity Rule, following its acquisition of Psyga Bio Ltd. and a subsequent equity raise. The company will be subject to a Mandatory Panel Monitor for one year starting July 20, 2026. XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on developing and improving the lives of patients with various diseases.

XTL Biopharmaceuticals Ltd. consummated its acquisition of Psyga Bio Ltd. on June 30, 2026, acquiring approximately 83.40% of Psyga Bio's share capital through the issuance of ADSs representing up to 33.36% of XTL's issued and outstanding capital. The transaction includes milestone-based additional ADS or warrant issuance representing up to 25% of the Company's capital. Concurrently, the company completed a following private placement of US$1,500,000 at US$2.70 per ADS, which included warrants with adjustable exercise prices. XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on expanding its asset portfolio with IP-based assets.

On June 29, 2026, shareholders approved the acquisition of 80% to 100% of Psyga Bio Ltd. via the issuance of shares and milestone warrants. Shareholders also approved a private placement of up to $1,500,000 from Alexander Rabinovitch and other investors, conditional upon the acquisition. Additionally, the company's authorized share capital will increase by 2,900,000,000 shares to a total of 5,800,000,000 ordinary shares. BARZILY & CO. C.P.A was appointed as the independent registered public accounting firm for the year ending December 31, 2025. XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on developing medical treatments.